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Abstract 
Haploidentical hematopoietic cell transplantation (haplo-HCT) is being increasingly used in 
acute leukemia patients as an alternative transplant modality when matched sibling or matched 
unrelated donors are unavailable. As several potential haploidentical relative donors are typically 
available for a given patient, optimizing donor selection to improve clinical outcome is crucial. 
The impact of donor age and kinship on the outcome of acute leukemia patients is not clearly 
established in this setting. Using the multinational registry of the acute leukemia working party 
of the European society for blood and marrow transplantation we retrospective analyzed the 
clinical outcome of 1270 acute myeloid leukemia and acute lymphoblastic leukemia patients who 
underwent haplo-HCT between 2005 and 2015. Patients over the age of 40 were significantly 
affected by increasing donor age resulting in higher non-relapse mortality (NRM) [Hazard ratio 
(HR)=1.86, confidence interval (CI) 95%, 1.18–2.94; P=0.007], inferior leukemia-free survival 
(LFS) (HR=1.59, CI 95%, 1.13–2.24; P=0.007), and overall survival (OS) (HR=1.74, CI 95%, 
1.22–2.47; P=0.002) when donors were over the age of 40. Additionally, kinship was found to be 
prognostically significant as patients transplanted from children donors over the age of 35 
experienced an increased rate of NRM (HR=1.82, CI 95%, 1.13–2.9; P=0.01), inferior LFS 
(HR=1.5,  CI  95%,  1.05–2.13;  P=0.03),  and  OS  (HR=1.5,  CI  95%,  1.04–2.15; P=0.03). For 
patients younger than 40 years, donor age and kinship were mostly not clinically impactful. Our 
data establish donor age and kinship as significant determinants of outcome following haplo- 
HCT for acute leukemia patients.
  
 
 
 
Introduction 
With the introduction of innovative immunosuppression strategies enabling stem cell 
engraftment across broad HLA disparity, thus mitigating the incidence of lethal graft versus host 
disease (GVHD) and transplantation associated mortality and toxicity[1, 2], the routine 
implementation of haploidentical hematopoietic cell transplantation (haplo-HCT) is gaining 
considerable traction in hematological malignancies[3-5]. The use of haplo-HCT affords the 
distinct advantage of a readily available related donor pool allowing for avoidance of the 
potentially hazardous delay caused by the search for matched unrelated donors. Initially 
however, this potential gain of haplo-HCT was counterbalanced by an increased risk of immune 
related complications. Notwithstanding these early concerns, several studies now report 
comparable outcomes following haplo-HCT and transplant from HLA matched sibling and 
unrelated donors[6-8]. Accordingly, capitalizing on the relative abundance of possible donors 
available for prospective haplo-HCT patients, potentially allows for refinement of donor 
selection with the aim of matching patients with the most compatible donor. Whereas donor- 
specific HLA antibodies[9], ABO compatibility[10], and donor-recipient kinship[11] have been 
clearly shown to affect outcome in diverse clinical settings in haplo-HCT, the impact of donor 
age on the outcome of acute leukemia patients is not as clearly established. A previously 
published single center analysis of patients with various hematological malignancies indicated 
that patients with young male donors experienced better outcomes[12], yet it remains unclear 
whether these results are applicable to acute leukemia patients and furthermore whether 
optimization of donor selection is affected by the age of patients as well as that of donors. 
Herein, we present the EBMT acute leukemia working party experience with 1270 patients who 
underwent related haplo-HCT for acute leukemia. Our data show a clear dichotomy between 
patients over the age of 40 who decidedly benefited from age and kinship matching as opposed  
to younger patients for whom matching of age and kinship did not impact significantly on 
clinical outcome. 
   
 
 
 
 
Methods 
Study Design and Data Collection 
The current analysis was a retrospective multicenter analysis performed by the Acute Leukemia 
Working Party (ALWP) of the European Society for Blood and Marrow Transplantation 
(EBMT). Quality control measures of the multicenter registry include confirmation of the 
validity of the entered data by the reporting team, cross-checking with the national registries, and 
regular in-house and external data audits. Eligibility criteria for the current study included adult 
patients with acute leukemia (i.e. AML, ALL) over the age of 18 who underwent a first T-cell 
replete related haplo-HCT from 2005 through 2015. Per study protocol, patients younger than 40 
were included in the analysis if their donors were either parent or sibling, whereas patients over 
the age of 40 were included if their donors were either sibling or children. The list of 
participating institutions is available in the supplementary appendix. The study was conducted in 
accordance with the Declaration of Helsinki and Good Clinical Practice guidelines and approved 
by the ALWP institutional review board. All patients provided written informed consent 
authorizing the use of their personal information for research purposes. 
Statistical Analysis 
The main endpoints of the study were non-relapse mortality (NRM), defined as death without 
previous relapse; relapse incidence (RI), defined on the basis of morphological evidence of 
leukemia in bone marrow or other extramedullary organs; leukemia-free survival (LFS), defined 
as the time from transplantation to first event (either relapse or death in complete remission); 
refined GVHD-free/relapse-free survival (GRFS), defined as survival without the following 
events: grade 3-4 acute GVHD, severe cGVHD, disease relapse, or death from any cause after 
Haplo-SCT[13]; and overall survival. Cumulative incidence  curves were used for RI and NRM 
in a competing risks setting, since death and relapse are competing. Probabilities of OS, LFS,  
and GRFS were calculated using the Kaplan–Meier estimate. The probabilities of NRM, RI, 
acute and chronic GVHD were calculated using the cumulative incidence estimator to 
accommodate for competing risks[14]. Univariate analyses were done using the Gray’s test for 
cumulative incidence functions and the log rank test for OS, GRFS, and LFS. A Cox 
proportional hazards model was used for multivariate regression. Variables included in 
multivariate models were either significantly or unbalanced between the donor age groups, or 
known to have an impact on outcome studied. Results were expressed as the hazard ratio (HR) 
with the 95% confidence interval (95% CI). Proportional hazards assumptions were checked 
systematically for all proposed models using the Grambsch-Therneau residual-based test. 
Initially we included both donor age and kinship as continuous variables in the Cox regression 
model. As the assumption of log-linearity (linearity between HR in each quintiles of donor age 
and outcome) was not verified, we categorized donor age using a cutoff of 40 years as planned in 
the protocol. Since donor age was related to kinship in the two cohorts of patients (over or under 
the age of 40), we also investigated the association between donor age and outcome in 4 groups 
of patients: 1. patients less than 40 years of age transplanted from a parent; 2. patients under the 
age of 40 transplanted from a sibling; 3. patients over 40 years of age transplanted from a child; 
  
 
 
4. patients more than 40 years of age transplanted from a sibling. In each group, we then 
determined the optimal threshold of donor age (i.e. best predictor of clinical outcome) using 
methodology previously described by Hothorn and Zeileis[15]. 
All tests were two-sided with the type I error rate fixed at 0.05. Statistical analyses were 
performed with SPSS 22.0 (SPSS Inc, Chicago, IL, USA) and R 3.2.3 (R Development Core 
Team, Vienna, Austria) software packages. 
 
 
Results 
Patient characteristics 
In all, 1270 patients underwent haploidentical HCT between 2005 and 2015, of whom 700 were 
transplanted at age 40 or over and 570 were transplanted at an age less than 40. Median follow- 
up for patients in this analysis was 27 months (range 0.6-119 months). Patient, disease and 
transplant characteristics are summarized in Table 1. 
Transplant outcomes 
At 2 years of follow-up for the entire cohort, LFS and RI rates were 43.6% (95% CI: 40.7-46.5) 
and 28.9% (95% CI: 26.3-31.5), respectively. The 2 year incidence of grade II-IV acute GVHD 
and chronic GVHD were 30.7% (95% CI: 28.1-33.3) and 31.2% (95% CI: 28.5-33.9), 
respectively. The rate of NRM was 27.3% (95% CI: 24.8-29.8) while the 2 year OS was 48.8% 
(95% CI: 45.8-51.7). The 2 year rate of GRFS was 34.9 % (95% CI: 32.1-37.7). Leukemia 
relapse, infection, and GVHD were the main etiologies for patient death both in patients under 
and over the age of 40 (supplementary table 1). 
 
 
Impact of donor age on patient outcome in patients over the age of 40 
To determine the differential impact of donor age on patient outcome, we proceeded with a 
separate analysis for patients over and under the age of 40. As shown in supplementary table 2 
which summarizes the baseline characteristics of patients over the age of 40, patients with 
younger donors tended to be older (57 vs. 53; P=0.032) whereas donors younger than 40 years of 
age were for the most part children of the patients (91% vs. 19%; P<0.001) as opposed to older 
donors who were mostly siblings (80% vs. 8%; P<0.001). Next, a univariate analysis comparing 
the clinical outcomes of patients in this age group was carried out to determine whether outcome 
differed among patients with donors over and under the age of 40, and according to donor 
kinship, namely sibling donor versus child donor. As shown in supplementary table 3, patients 
with younger donors experienced improved LFS and OS rates compared to their counterparts 
with older donors (41% vs. 32%; P=0.03, and 45% vs. 35%; P=0.01, respectively). In this age 
group of patients over 40, kinship did not impact on patient outcome in a statistically significant 
manner, thus patients had comparable outcomes whether they were transplanted from their 
sibling or child. 
   
 
 
 
 
 
 
We then carried out a multivariate analysis (table 2) which revealed that patients older than 40 
experienced increased NRM (HR=1.86, CI 95%, 1.18–2.94; P=0.007) as well as inferior LFS 
(HR=1.59, CI 95%, 1.13–2.24; P=0.007), OS (HR=1.74, CI 95%, 1.22–2.47; P=0.002), and 
GRFS (HR=1.6, CI 95%, 1.16–2.22; P=0.004) rates when donor age was more than 40 years of 
age. 
Focused assessment of optimal donor subsets for patients over the age of 40 
To better characterize the specific patient subsets which would benefit from specific donor pools, 
we made use of methodology previously described by Hothorn and Zeileis[15], allowing us to 
determine that the optimal discriminating age cutoff for prognostication was 35 years and 41 
years for children donors and sibling donors, respectively. As shown in supplementary figure 1 
and supplementary table 4, patients transplanted from their children had inferior NRM, LFS, OS, 
and GRFS rates when the donors’ age was over 35. In the multivariate analysis presented in table 
3, transplantation from children donors over the age of 35 was associated with an increased risk 
of NRM (HR=1.82, CI 95%, 1.13–2.9; P=0.01), inferior LFS (HR=1.5, CI 95%, 1.05–2.13; 
P=0.03), and inferior OS (HR=1.5, CI 95%, 1.04–2.15; P=0.03). Subsequently, we performed 
univariate and multivariate analyses for patients transplanted from sibling donors with age 41 as 
the cutoff. While a univariate analysis indicated that using a sibling donor over the age of 41 was 
associated with inferior NRM, LFS, and OS rates, the multivariate analysis summarized in 
supplementary table 5, did not confirm the statistical significance of these associations. 
Impact of donor age on patient outcome in younger patients under the age of 40 
The baseline characteristics of the subgroup of patients under the age of 40 are summarized in 
supplementary table 6. Patients with younger donors tended to be older (29 years vs. 25 years; 
P<0.0001) whereas patients with younger donors were more likely to have male donors as 
opposed to older donors who tended to be females (P=0.001). Next, a univariate analysis was 
performed to evaluate the impact of donor age and donor kinship on clinical outcome. As shown 
in supplementary table 7, the risk for grade II-IV acute GVHD was markedly increased in 
patients whose donors were over the age of 40 compared to patients with younger donors (38% 
vs. 28%; P=0.014). The only clinical outcome affected by kinship was the incidence of grade II- 
IV acute GVHD which was significantly higher in patients with parent donors compared to 
patients transplanted from their siblings (38% vs. 28%; P=0.017). The multivariate analysis 
shown in supplementary table 8 revealed that in patients under the age of 40, having a donor over 
the age of 55 was independently associated with a decreased risk for extensive chronic GVHD 
(HR=0.17, CI 95%, 0.02–0.95; P=0.045) concomitant with a trend for an increased risk of 
relapse (HR=1.85, CI 95%, 0.97–3.49; P=0.058). 
Focused assessment of optimal donor subsets for patients younger than 40 
In line with the subgroup analysis performed above, we wanted to determine specifically in 
younger patients whether donor age affected prognosis with respect to kinship. In this patient age 
group it was determined that for parent donors, the optimal cutoff age was 51, and as 
  
 
 
summarized in supplementary table 9, a multivariate analysis indicated that when donor age was 
more than 51 years of age, there was a trend towards increased RI (HR=1.82, CI 95%, 0.97–3.38; 
P=0.06) and LFS (HR=1.6, CI 95%, 0.98–2.58; P=0.057) rates. The equivalent analysis in 
sibling donors did not reveal any significant associations with donor age for this group of 
patients (data not shown). Figure 1 outlines LFS and OS of patients according to patient and 
donor age. 
 
 
Discussion 
As haplo-HCT is transitioning into the mainstream of the stem cell transplantation field,  
choosing the best available donor is becoming a major priority. Our data suggest age 40 as a 
prognostically meaningful threshold with significant practical implications for patients, wherein 
patients over the age of 40 may benefit from a younger donor especially when the donor is their 
child. Conversely, we show that for patients under the age of 40, donor age for the most part is 
not as clinically significant. 
Recently published donor selection algorithms for haplo-HCT[16-18] have designated a myriad 
of clinical[11, 12], serological[9, 10, 19], and immunological[20] parameters constituting the 
backbone for optimal donor selection in this setting. Whereas most of these have not been 
rigorously validated for haplo-HCT, a particular emphasis has been placed on donor age as this 
parameter is readily available and potentially modifiable when considering a specific donor from 
a potential donor pool consisting of several siblings and children. The theme of donor age has 
been extensively investigated in hematopoietic cell transplantation in the past three decades with 
data generally confirming that patients receiving grafts from younger donors experience superior 
survival[21-25] concomitant to a decreased incidence of acute and chronic GVHD[26, 27]. 
Our analysis shows that in patients over the age of 40, having an older donor, namely over the 
age of 40, is tightly associated with increased NRM and inferior LFS translating into inferior OS. 
Moreover, in this age group we established kinship to be a major determinant of patient outcome 
as increasing donor age did not affect outcome when patients were transplanted from their 
siblings whereas those patients receiving grafts from their children did experience worse 
outcome when their donor was over the age of 35. Our findings are generally in line with those  
of Wang and colleagues[12] with several noteworthy exceptions. In contrast to their results we 
did not find male gender to be significantly associated with superior clinical outcome, nor did we 
observe children donors to be superior to sibling donors in terms of GVHD. These differences 
may be accounted for by considering several factors: our analysis was restricted to a uniform 
cohort of acute leukemia patients whereas theirs consisted of a mixed cohort which comprised a 
substantial segment of patients with diseases other than acute leukemia. Additionally, post- 
transplantation cyclophosphamide was widely used for patients in our analysis while the Chinese 
analysis uniformly used ATG for T-cell depletion. 
Interestingly, we found that for younger patients, donor age and kinship were not as clinically 
impactful. The only clear association in this age group pertained to a decreased rate of extensive 
chronic GVHD when donors were over the age of 55, an observation which diverges from 
  
 
 
 
previously published data in matched unrelated donors[21, 26]. The reasons for this observation 
are not completely clear but we note that as part of the aging process there is an increase in the 
number of peripheral blood CD4
+
CD25
+
 regulatory T cells, as shown previously in healthy 
volunteers[28], which may attenuate immune responsiveness and result in decreased GHVD. 
We believe that the implications of our findings are of importance for future donor selection 
algorithms in haplo-HCT and will guide clinicians in making a rationale determination of the 
optimal donor for a specific patient. Furthermore, our findings underscore the unique 
immunological milieu of haplo-HCT where considerations need to be made regarding donor- 
recipient rapports between patients, their children, siblings, and parents. 
As with any multicenter registry analysis, our results should be interpreted cautiously owing to 
inherent biases in data collection and variations in clinical practice among participating 
institutions. Additionally, we note that the group of patients over the age of 40 who were 
transplanted from younger donors (under the age of 41) consisted of only 47 patients and thus the 
lack of statistical significance (P=0.06) with regard to OS and LFS may have resulted from the 
lack of sufficient statistical power. 
In aggregate, the key findings of this analysis uncover an additional facet of the complexities 
involved in providing the best outcome for acute leukemia patients undergoing haplo-HCT, and 
will hopefully further inform the maturing field of haploidentical transplantation. 
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Figure legends 
Figure 1. Transplantation outcomes of acute leukemia patients stratified per patient and donor 
age. 
A- Leukemia free survival in patients over the age of 40 
B- Leukemia free survival in patients under the age of 40 
C- Overall survival in patients over the age of 40 
D- Overall survival in patients under the age of 40 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Table 1. Patient, disease and HCT characteristics stratified per age at transplant 
 
Variable, n (%) Patient age<40 (n=570) Patient age≥40 (n=700) P 
Follow up duration in m, median (range) 30 (0.62 - 119.3 ) 24 (0.89-102.16 ) <0.001 
Patient age in y, median (range) 27 (18-40) 55 (40-77) <0.001 
Donor age in y, median (range) 43 (13-72) 36 (13-71) <0.001 
Gender   0.16 
Male 348 (61.1) 401 (57)  
Female 221 (38.8) 299 (42.7)  
Year of transplant, median (range) 2012(2005-2015) 2013(2005-2015) <0.001 
AML 400 (70.1) 619 (88.4) <0.001 
ALL 170 (29.8) 81 (11.5)  
Disease status at transplant   <0.001 
CR1 325 (57) 324 (46.2)  
CR2/3 125 (21.9) 124 (17.7)  
Active disease 120 (21) 252 (36)  
ELN AML cytogenetic risk category   <0.001 
Favorable 39 (11.9) 27 (5.6)  
Intermediate 236 (72.1) 322 (67.6)  
Adverse 52 (15.9) 127 (26.6)  
Missing 73 143  
ALL Philadelphia chromosome status 0.001 
Negative 68 (51.5) 17 (26.1)  
Positive 64 (48.4) 48 (73.8)  
Missing 37 16  
Donor-patient kinship <0.001 
Parent 298 (52.2) 0  
Child 0 440 (62.8)  
Sibling 272 (47.7) 260 (37.1)  
Donor-recipient gender matching 0.031 
Male-Male 184 (32.3) 248 (35.4)  
Female-Male 164 (28.8) 153 (21.8)  
Male-Female 118 (20.7) 171 (24.4)  
Female-Female 103 (18.1) 128 (18.2)  
CMV Donor-recipient matching   <0.001 
CMV D-/R- 62 (11.1) 97 (14.1)  
CMV D+/R- 34 (6.1) 27 (3.9)  
CMV D-/R+ 49 (8.8) 164 (23.9)  
CMV D+/R+ 409 (73.8) 397 (57.9)  
Missing 16 15  
T-cell depletion in-vivo   <0.001 
Yes 321 (56.4) 247 (35.4)  
No 248 (43.5) 449 (64.5)  
Missing 1 4  
Use of PTCy   <0.001 
Yes 240 (42.4) 425 (61)  
No 325 (57.5) 271 (38.9)  
Missing 5 4  
Stem cell source   <0.001 
Bone marrow derived graft 171 (30) 290 (41.4)  
Peripheral blood graft 203 (35.6) 360 (51.4)  
Bone marrow and peripheral blood 196 (34.3) 50 (7.1)  
Engraftment   0.015 
Succesful engraftment 495 (94.2) 556 (90.4)  
Engraftment failure 30 (5.7) 59 (9.5)  
Missing 45 85  
Conditioning regimen   <0.001 
Myeloablative 426 (74.7) 287 (41)  
Reduced intensity 144 (25.2) 413 (59)  
AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CMV, cytomegalovirus; ELN, European LeukemiaNet; 
PTCy, post-transplant cyclophosphamide 
   
 
 
 
Table 2. Multivariate analysis of factors impacting on clinical outcome in patients over the age of 40 
 
 RI NRM LFS OS GRFS Grade II-IV aGVHD cGVHD 
 HR CI P HR CI P HR CI P HR CI P HR CI P HR CI P HR CI P 
Donor Age>40y 1.30 0.779 - 
2.165 
0.32 1.87 1.182 - 
2.945 
0.00 7 1.59 1.134 - 2.24 0.007 1.74 1.223 - 
2.475 
0.002 1.61 1.162 - 
2.227 
0.004 1.40 0.823 - 
2.376 
0.22 1.39 0.778 - 
2.469 
0.2 7 
Patient age (per 10y) 0.80 0.621 - 
1.021 
0.07 1.08 0.851 - 
1.369 
0 .529 0.93 0.782 - 
1.103 
0.40 0.95 0.798 - 
1.129 
0.56 0.85 0.7 22 - 1 0.05 0.79 0.619 - 
1.008 
0.06 0.89 0.682 - 
1.173 
0.42 
ALL vs. AML 1.32 0.811 - 
2.137 
0.27 1.32 0.833 - 
2.094 
0.23 7 1.29 0.925 - 
1.808 
0.13 1.26 0.893 - 1.77 0.19 1.22 0.884 - 
1.672 
0.23 0.94 0.566 - 
1.567 
0.82 1.04 0.608 - 
1.785 
0.88 
KPS≥80% 0.82 0.517 - 
1.303 
0.40 0.64 0.411 - 
1.006 
0.053 0.7 4 0.539 - 
1.027 
0.07 0.68 0.488 - 
0.939 
0.02 0.64 0.471 - 0.8 
81 
0.006 0.78 0.477 - 
1.269 
0.31 0.44 0.252 - 
0.781 
0.00 
Sibling vs. children 0.82 0.448 - 
1.489 
0.51 0.64 0.367 - 
1.097 
0.10 0.71 0.473 - 
1.065 
0.10 0.69 0.453 - 1.04 0.08 0.65 0.4 4 - 0.95 0.026 0.73 0.4 - 1.344 0.32 0.75 0.389 - 
1.456 
0.40 
RIC vs. MAC 1.38 0.971 - 
1.968 
0.07 1.09 0.785 - 
1.522 
0.60 1 .22 0.957 - 
1.556 
0.11 1.19 0.928 - 
1.526 
0.17 1.25 0.99 - 1. 
577 
0.06 1.08 0.767 - 
1.526 
0.65 1.00 0.679 - 
1.461 
0.98 
PB vs. BM stem cell 
source 
0.82 0.559 - 
1.19 
0.29 1.27 0.894 - 
1.798 
0.18 1.04 0.798 - 
1.348 
0.79 1.01 0.775 - 1.31 0.96 1.1 6 0.906 - 
1.481 
0.24 1.77 1.267 - 
2.467 
<0.0001 1.45 0.935 - 
2.239 
0.10 
Female patient vs. male 1.37 1.004 - 
1.871 
0.047 1.01 0.748 - 1.3 
67 
0.94 1.18 0.949 - 
1.462 
0.14 1.08 0.866 - 
1.353 
0.49 1.04 0 .843 - 
1.277 
0.73 0.93 0.678 - 
1.283 
0.67 1.31 0.921 - 
1.863 
0.13 
Female donor vs. male 0.73 0.532 - 
1.006 
0.055 0.97 0.714 - 1.3 
09 
0.83 0.84 0.677 - 1.05 0.13 0.86 0.684 - 
1.076 
0.18 0.89 0. 718 - 
1.093 
0.26 1.16 0.849 - 1.59 0.35 1.06 0.744 - 
1.501 
0. 76 
RIC, reduced intensity conditioning; MAC, myeloablative conditioning; PB, peripheral blood; BM, bone marrow 
 
 
 
 
Table 3. Multivariate analysis of factors impacting on clinical outcome of patients over 40 with children donors 
 
 RI NRM LFS OS GRFS Grade II-IV aGVHD cGVHD 
 HR CI P HR CI P HR CI P HR CI P HR CI P HR CI P HR CI P 
Donor Age>35y 1.15 0.683 - 1.941 0.60 1.82 1.137 - 
2.907 
0.01 1.50 1.051 - 
2.139 
0.03 1.50 1.049 - 
2.151 
0.03 1.38 0 .978 - 
1.934 
0.067 1.04 0.623 - 
1.748 
0.87 1.03 0.584 - 
1.808 
0.92 
Patient age (per 10y) 0.82 0.587 - 1.146 0.25 0.91 0.66 - 1.257 0.57 0.86 0.676 - 
1.095 
0.22 0.95 0.742 - 
1.205 
0. 65 0.81 0.644 - 
1.016 
0.068 0.97 0.692 - 
1.372 
0.88 1.18 0. 82 - 1.69 0.38 
ALL vs. AML 1.44 0.733 - 
2.816 
0.29 1.22 0.621 - 2.39 0.57 1.31 0.808 - 
2.135 
0.27 1.36 0.835 - 
2.227 
0.22 1.19 0.74 3 - 
1.907 
0.47 0.92 0.432 - 1.95 0.82 0.91 0.4 - 2.06 0.82 
KPS≥80% 1.15 0.636 - 
2.077 
0.65 1.26 0.759 - 
2.098 
0.37 1. 21 0.813 - 
1.801 
0.35 1.27 0.851 - 
1.904 
0.24 1.23 0.845 - 
1.789 
0.28 1.13 0.651 - 
1.962 
0.66 1.29 0.747 - 2.24 0.36 
Active disease vs. CR1 0.72 0.399 - 1.287 0.26 0.53 0.302 - 0.919 0.02 0.65 0.432 - 
0.988 
0.04 0.60 0.39 - 0.908 0.02 0.48 0.321 - 0.72 0.0004 0.53 0.293 - 
0.971 
0.04 0.50 0.255 - 
0.984 
0.045 
RIC vs MAC 1.16 0.739 - 
1.811 
0.52 1.55 1.003 - 
2.399 
0.049 1.41 1.016 - 
1.951 
0.04 1.40 1.003 - 1.94 0.048 1.60 1.1 71 - 
2.192 
0.0032 1.13 0.726 - 
1.772 
0.58 1.17 0.74 - 1.8 51 0.50 
PB vs. BM stem cell 
source 
0.84 0.519 - 1.358 0.48 1.24 0.799 - 
1.908 
0.34 1.09 0.751 - 
1.566 
0.66 1.06 0.743 - 1 .51 0.75 1.09 0.766 - 
1.552 
0.63 1.39 0.924 - 
2.084 
0.11 1. 49 0.969 - 
2.297 
0.069 
Female patient vs. male 1.44 0.972 - 2.143 0.07 1.13 0.774 - 1.65 0.53 1.29 0.977 - 
1.711 
0.07 1.25 0.935 - 
1.661 
0.13 1.14 0.869 - 
1.495 
0.34 1.09 0.717 - 
1.656 
0.69 2.00 1 .275 - 
3.134 
0.003 
Female donor vs. male 0.75 0.497 - 1.124 0.16 1.12 0.766 - 1.64 0.56 0.89 0.668 - 
1.178 
0.41 0.92 0.687 - 
1.232 
0. 58 0.95 0.724 - 
1.253 
0.73 1.11 0.738 - 
1.671 
0.62 0.82 0.5 28 - 
1.263 
0.36 
RIC, reduced intensity conditioning; MAC, myeloablative conditioning; PB, peripheral blood; BM, bone marrow 
   
 
 
 
 
 
 
 
 
 
Figure 1. Transplantation outcomes of acute leukemia patients stratified per patient and donor age. 
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